These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 33554836)

  • 21. Immune Cell Hacking: Challenges and Clinical Approaches to Create Smarter Generations of Chimeric Antigen Receptor T Cells.
    Elahi R; Khosh E; Tahmasebi S; Esmaeilzadeh A
    Front Immunol; 2018; 9():1717. PubMed ID: 30108584
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Chimeric antigen receptor T cell (CAR-T) therapy for refractory/relapsed hematological malignancy].
    Hiramatsu H
    Rinsho Ketsueki; 2018; 59(10):1948-1954. PubMed ID: 30305496
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and toxicity for CD22/CD19 chimeric antigen receptor T-cell therapy in patients with relapsed/refractory aggressive B-cell lymphoma involving the gastrointestinal tract.
    Zeng C; Cheng J; Li T; Huang J; Li C; Jiang L; Wang J; Chen L; Mao X; Zhu L; Lou Y; Zhou J; Zhou X
    Cytotherapy; 2020 Mar; 22(3):166-171. PubMed ID: 32063474
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Adoptive therapy with TCR gene-modified T cells for hematological malignancies and solid tumors].
    Ikeda H
    Rinsho Ketsueki; 2019; 60(6):716-722. PubMed ID: 31281165
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Manufacturing development and clinical production of NKG2D chimeric antigen receptor-expressing T cells for autologous adoptive cell therapy.
    Murad JM; Baumeister SH; Werner L; Daley H; Trébéden-Negre H; Reder J; Sentman CL; Gilham D; Lehmann F; Snykers S; Sentman ML; Wade T; Schmucker A; Fanger MW; Dranoff G; Ritz J; Nikiforow S
    Cytotherapy; 2018 Jul; 20(7):952-963. PubMed ID: 30180944
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Updates on CAR T-cell therapy in B-cell malignancies.
    Jacoby E; Shahani SA; Shah NN
    Immunol Rev; 2019 Jul; 290(1):39-59. PubMed ID: 31355492
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chimeric antigen receptor-engineered T-cell therapy for liver cancer.
    Chen Y; E CY; Gong ZW; Liu S; Wang ZX; Yang YS; Zhang XW
    Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):301-309. PubMed ID: 29861325
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combining the best of two worlds: highly flexible chimeric antigen receptor adaptor molecules (CAR-adaptors) for the recruitment of chimeric antigen receptor T cells.
    Darowski D; Kobold S; Jost C; Klein C
    MAbs; 2019; 11(4):621-631. PubMed ID: 30892136
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CAR-T treatment for hematological malignancies.
    Atrash S; Bano K; Harrison B; Abdallah AO
    J Investig Med; 2020 Jun; 68(5):956-964. PubMed ID: 32200355
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anti-CD19 chimeric antigen receptor-modified T cells for B-cell malignancies: a systematic review of efficacy and safety in clinical trials.
    Zhu Y; Tan Y; Ou R; Zhong Q; Zheng L; Du Y; Zhang Q; Huang J
    Eur J Haematol; 2016 Apr; 96(4):389-96. PubMed ID: 26115358
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CAR-T cell and Personalized Medicine.
    Cruz-Ramos M; García-Foncillas J
    Adv Exp Med Biol; 2019; 1168():131-145. PubMed ID: 31713169
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical investigation of CAR T cells for solid tumors: Lessons learned and future directions.
    Bagley SJ; O'Rourke DM
    Pharmacol Ther; 2020 Jan; 205():107419. PubMed ID: 31629009
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chimeric Antigen Receptor T Cell Based Immunotherapy for Cancer.
    Li F; Zhang T; Cao L; Zhang Y
    Curr Stem Cell Res Ther; 2018; 13(5):327-335. PubMed ID: 29676233
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial.
    Shah NN; Johnson BD; Schneider D; Zhu F; Szabo A; Keever-Taylor CA; Krueger W; Worden AA; Kadan MJ; Yim S; Cunningham A; Hamadani M; Fenske TS; Dropulić B; Orentas R; Hari P
    Nat Med; 2020 Oct; 26(10):1569-1575. PubMed ID: 33020647
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chimeric Antigen Receptor T-Cells for the Treatment of B-Cell Acute Lymphoblastic Leukemia.
    Tomuleasa C; Fuji S; Berce C; Onaciu A; Chira S; Petrushev B; Micu WT; Moisoiu V; Osan C; Constantinescu C; Pasca S; Jurj A; Pop L; Berindan-Neagoe I; Dima D; Kitano S
    Front Immunol; 2018; 9():239. PubMed ID: 29515572
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Prospect for chimeric antigen receptor-engineered T cell immunotherapy for solid tumors].
    Zhou SY; Shi YK
    Zhonghua Zhong Liu Za Zhi; 2018 Jul; 40(7):490-492. PubMed ID: 30060355
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [New Research Advances on Chimeric Antigen Receptor T Cells in the Treatment of Relapsed and Refractory Multiple Myeloma-Review].
    Zhang FR; Li X; Liu J
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Aug; 27(4):1316-1320. PubMed ID: 31418399
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Advances in chimeric antigen receptor T cells therapy in the treatment of breast cancer.
    He Q; Hu H; Yang F; Song D; Zhang X; Dai X
    Biomed Pharmacother; 2023 Jun; 162():114609. PubMed ID: 37001182
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adoptive cell transfer therapy for hepatocellular carcinoma.
    Zhang R; Zhang Z; Liu Z; Wei D; Wu X; Bian H; Chen Z
    Front Med; 2019 Feb; 13(1):3-11. PubMed ID: 30659408
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CAR‑T cell therapy: A breakthrough in traditional cancer treatment strategies (Review).
    Sun D; Shi X; Li S; Wang X; Yang X; Wan M
    Mol Med Rep; 2024 Mar; 29(3):. PubMed ID: 38275119
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.